Zealand Pharma sells rusfertide royalty rights to Royalty Pharma for $100M

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/8/2026

1. SPCX
2. SBUX
3. LEVI
4. NVDA
5. GOOGL
6. ORCL
7. USO
8. STZ
9. AAPL
10. SPY

Go back to Zealand Pharma sells rusfertide royalty rights to Royalty Pharma for $100M

Zealand Pharma enters into a USD 100 million royalty purchase and sale agreement with Royalty Pharma for the economics related to rusfertide

August 12, 2026 4:05 PM EDT

Company announcement No. 38 / 2026

Zealand Pharma enters into a USD 100 million royalty purchase and sale agreement with Royalty Pharma for the economics related to rusfertide

Zealand Pharma will receive USD 100 million for the sale of its economic interests related to rusfertide, including royalty rights on the potential future global net sales of rusfertide.The agreement unlocks value from a non-core royalty entitlement for redeployment to Zealand Pharmas key strategic priorities.

Copenhagen, Denmark, August 12, 2026 Zealand Pharma A/S (Nasdaq:... More